QNRX
Income statement / Annual
Last year (2023), Quoin Pharmaceuticals, Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Quoin Pharmaceuticals, Ltd.'s net income was -$8.69 M.
See Quoin Pharmaceuticals, Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$280,000.00
|
$0.00
|
-$280,000.00
|
$0.00
|
| Cost of Revenue |
$103,438.00 |
$103,635.00 |
$104,115.00 |
$104,773.00 |
$227,055.00 |
$125,720.00 |
$104,223.00 |
$89,130.00 |
$18,271.00 |
| Gross Profit |
-$103,438.00 |
-$103,635.00 |
-$104,115.00 |
-$104,773.00 |
-$227,055.00 |
-$405,720.00 |
-$104,223.00 |
-$369,130.00 |
-$18,271.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
1.45 |
0 |
1.32 |
0 |
| Research and Development
Expenses |
$3.31 M
|
$2.67 M
|
$1.56 M
|
$244,155.00
|
$45,650.00
|
$8.26 M
|
$5.89 M
|
$8.26 M
|
$1.52 M
|
| General & Administrative
Expenses |
$6.07 M
|
$6.58 M
|
$4.50 M
|
$1.43 M
|
$1.51 M
|
$7.97 M
|
$4.20 M
|
$7.97 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.07 M
|
$6.58 M
|
$4.50 M
|
$1.43 M
|
$1.51 M
|
$7.97 M
|
$4.20 M
|
$7.97 M
|
$1.06 M
|
| Other Expenses |
$0.00 |
$417,307.00 |
-$14.03 M |
-$378,333.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$9.38 M |
$9.26 M |
$6.06 M |
$1.67 M |
$1.56 M |
$16.22 M |
$10.10 M |
$16.22 M |
$2.58 M |
| Cost And Expenses |
$9.38 M |
$9.26 M |
$6.06 M |
$1.67 M |
$1.56 M |
$16.22 M |
$10.10 M |
$16.22 M |
$2.60 M |
| Interest Income |
$692,824.00 |
$95,745.00 |
$1,365.41 |
$47.02 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1,029.40 |
| Interest Expense |
$0.00 |
$714,081.00 |
$1.09 M |
$47,021.00 |
$412,292.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$103,706.00
|
$103,635.00
|
$104,115.00
|
$104,773.00
|
$227,055.00
|
$125,720.00
|
$104,223.00
|
$89,130.00
|
$18,271.00
|
| EBITDA |
-$9.27 M
|
-$8.74 M
|
-$21.37 M
|
-$2.01 M
|
-$1.54 M
|
-$5.47 M
|
-$7.80 M
|
-$3.91 M
|
-$2.60 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-54.7 |
0 |
-54.7 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-54.7
|
0
|
-54.7
|
0
|
| Total Other
Income/Expenses Net |
$691,931.00
|
-$123,792.00
|
-$1.09 M
|
-$425,354.00
|
$0.00
|
$2.54 M
|
-$1.06 M
|
$237,071.00
|
-$19,304.00
|
| Income Before Tax |
-$8.69 M |
-$9.38 M |
-$21.46 M |
-$2.10 M |
-$1.56 M |
$15.32 M |
$10.17 M |
$15.32 M |
-$2.62 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-54.7
|
0
|
-54.7
|
0
|
| Income Tax Expense |
$0.00 |
-$104,043.00 |
-$12.94 M |
-$331,312.00 |
$1.55 M |
-$161,141.00 |
-$1.17 M |
$147,942.00 |
-$1.00 |
| Net Income |
-$8.69 M |
-$9.28 M |
-$8.52 M |
-$1.76 M |
-$1.56 M |
$15.32 M |
$10.17 M |
$15.32 M |
-$2.62 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-54.7 |
0 |
-54.7 |
0 |
| EPS |
-9.64 |
-22.97 |
-322.49 |
-88.1 |
-440.29 |
7100.73 |
5450.81 |
10084 |
-2108.97 |
| EPS Diluted |
-9.64 |
-22.97 |
-322.49 |
-88.1 |
-440.29 |
7100.73 |
5450.81 |
10084 |
-2108.97 |
| Weighted Average Shares
Out |
$900,919.00
|
$403,883.00
|
$26,415.00
|
$20,024.00
|
$3,544.04
|
$2,157.10
|
$1,866.14
|
$1,518.81
|
$1,241.25
|
| Weighted Average Shares
Out Diluted |
$900,919.00
|
$403,883.00
|
$26,415.00
|
$20,024.00
|
$3,544.04
|
$2,157.10
|
$1,866.14
|
$1,518.81
|
$1,241.25
|
| Link |
|
|
|
|
|
|
|
|
|
